Brief: Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation For Elraglusib For The Treatment Of Pancreatic Cancer
07/01/2025 13:11
Jan 7 (Reuters) - Actuate Therapeutics Inc ACTU.O :
* ACTUATE THERAPEUTICS RECEIVES EMA ORPHAN MEDICINAL PRODUCT
DESIGNATION FOR ELRAGLUSIB FOR THE TREATMENT OF PANCREATIC
CANCER
* ACTUATE THERAPEUTICS INC: TO REPORT TOPLINE DATA FROM
PHASE 2
TRIAL OF ELRAGLUSIB IN 1H 2025
Source text: ID:nGNX6yJvNj
Further company coverage: ACTU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actuate Therapeutics
See all newsHealth Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Brief: Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
Brief: Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing
Brief: Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial
Brief: Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing